Release Date: September 30, 2024
Expiration Date: September 30, 2025
Activity Overview
Along the treatment continuum for patients with DLBCL, numerous decisions regarding treatment need to be made to ensure optimal outcomes. This also necessitates knowledge of the adverse events associated with each approach. In this educational activity, experts in the management of DLBCL discuss treatment options and their associated safety profiles, with practical advice on the best approaches for different toxicities that may jeopardize the success of therapy.
Target Audience
This online educational activity is primarily directed toward academic and community hematologists, oncologists, oncology nurses, oncology advanced practice providers, oncology pharmacists, and other health care providers involved in the diagnosis and management of patients with DLBCL.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Recognize adverse events associated with the different classes of targeted therapies used in R/R DLBCL
- Formulate strategies for the monitoring, identification, and mitigation of toxicities linked to targeted agents in patients with DLBCL
Matt Lunning, DO, FACP
Associate Professor
Medical Director, Cellular Therapy
Associate Vice-Chair Research, Department of Medicine
Assistant Vice Chancellor for Clinical Research
Fred & Pamela Buffett Cancer Center
University of Nebraska Medical Center
Omaha, NE
Disclosures: Grant/Research Support: AbbVie, Bristol Myers Squibb, Fate Therapeutics, Kite/Gilead, Sana Therapeutics; Consultant: AbbVie, Acrotech, ADC Therapeutics, AstraZeneca, Bristol Myers Squibb, Caribou, CRISPR, Daiichi Sankyo, Fate Therapeutics, Genentech, GenMab, Incyte, Ipsen, Janssen, Kite/Gilead, Loxo/Lilly, Recordati, Regeneron, SeaGen/Pfizer, ViTToria.
Kami Maddocks, MD
Professor-Clinical, Division of Hematology
Director, Lymphoma Program
Associate Division Director for Ambulatory Operations, Division of Hematology
Medical Director, Infusion Services
Associate Chief Medical Officer, The James Cancer Hospital
Chief of Staff - Elect, The James Cancer Hospital
The Ohio State University Comprehensive Cancer Center
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Colombus, OH
Disclosures: Consultant: AbbVie, ADC Therapeutics, AstraZeneca, Bristol Myers Squibb, Eli Lily and Company, Genentech, Incyte, Janssen, Kite Pharmaceuticals, MorphoSys.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
